Title

Comparative Effect Study Between Distal-proximal Point Association and Local Distribution Point Association in Chemotherapy-induced Nausea and Vomiting
  • Phase

    N/A
  • Study Type

    Interventional
  • Status

    Unknown status
  • Intervention/Treatment

    urea ramosetron tropisetron ...
  • Study Participants

    240
The purpose of this study is to clarify whether distal-proximal point association is more effective than partial match point association by electro-acupuncture in the management of chemotherapy-induced nausea and vomiting .
Study Started
Jun 30
2015
Primary Completion
Jun 30
2016
Anticipated
Study Completion
Sep 30
2016
Anticipated
Last Update
Jun 23
2015
Estimate

Drug only antiemetic (Ramosetron, Tropisetron and dexamethasone)

The control group will receive standard antiemetic alone. Standard antiemetic for all groups is based on American Society of Clinical Oncology clinical practice guideline. 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron) and dexamethasone are supplied from the first day of chemotherapy, and lasting for 3-5 days.And plus antiemetic drug as the comparator group.

Other Matching points ST36+CV12 plus antiemetic drug

Choose both Zusanli(ST36) and Zhongwan point(CV12). Manipulating until achieving a "de Qi" sensation, then the needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days.And plus antiemetic drug as the comparator group.

Other Matching points PC6+CV12 plus antiemetic drug

Choose both Neiguan(PC6) and Zhongwan point(CV12). Manipulating until achieving a "de Qi" sensation, then the needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days.And plus antiemetic drug as the comparator group.

Other Matching points CV13+CV12 plus antiemetic drug

Choose both Shangwan(CV13) and Zhongwan point(CV12). Manipulating until achieving a "de Qi" sensation, then the needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days.And plus antiemetic drug as the comparator group.

only antiemetic Active Comparator

The participants in the control group received standard antiemetic alone. Standard antiemetic for all groups is based on American Society of Clinical Oncology cClinical pPractice gGuideline. The 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron) and dexamethasone are administered before the chemotherapy treatment.

Matching points ST36+CV12 Experimental

Matching points PC6+CV12 Experimental

Matching points CV3+CV12 Experimental

Criteria

Inclusion Criteria:

Be diagnosed as cancer and need to accept chemotherapy.
The score of Karnofsky ≥70
Patients of either gender and older than 18 years
Patients receiving chemotherapy both outpatients and inpatients
Patients receiving chemotherapy either the first or multiple cycle, but the patient will be taken in only one time
To receive chemotherapy containing cisplatin(DDP≥75mg/m2) or joint chemotherapy programmes of Anthracyclines(Adriamycin≥40mg/m2 or epirubicin≥60mg/m2)
Life expectancy≥ 6 months
Willing to participate in the study and be randomized into one of the four study groups.

Exclusion Criteria:

To receive radiotherapy and chemotherapy
Gastrointestinal tumors
Patients with serious liver disease or abnormal hepatorenal function (AST,ACT, and TBIL are 3 times more than normal, BUN and Cr are 2 times more than normal)
Presence of cardiac pacemaker
Active skin infection
Nausea and/or vomiting resulting from opioids or metabolic imbalance (electrolyte disturbances)
Patients unable to provide self-care or communication
Nausea and/or vomiting resulting from mechanical risk factors (i.e., intestinal obstruction)
Brain metastases
Women in pregnant and lactating period
No Results Posted